CAMELLIA: Study to Evaluate the Effect of Long-Term Treatment with BELVIQ (lorcaserin HC1) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors.
PHASE: Follow Up (not accepting new patients)
Principal Investigator: Brendan J. Cavanaugh, MD, FACC
Mihaela Bujoi, MD, FACC
Barry Ramo, MD, FACC
Karen Sopko, MD, FACC
Mel Peralta, MD, FACC